Sage Therapeutics has a green light for postpartum depression drug Zulresso. But it also has some big challenges ahead.
Just a week after Roche’s Tecentriq became the first FDA-approved I-O agent in breast cancer, the drug has clinched another first-in-class nod.
If it’s March, it must be #FierceMadness, our annual take on the March Madness NCAA basketball tournament and bracket mania—with a pharma twist.
Comedian and TV host Jay Leno teamed with Amgen, maker of the PCSK9 drug Repatha, for a 'Cholesterol 911' awareness push.
The fish oil-derived drug showed significant reduction not just in first cardiovascular events, but in recurrent incidence as well.
Eliquis has new data showing the next-gen anticoagulant is safer than warfarin for a tough-to-treat group of atrial fibrillation patients.
The first FDA drug marketing warning letter of the year goes to ... a drug that’s not yet approved.
Despite pricing pressure from domestic rivals, Keytruda could still generate billions of dollars a year in China, Cantor analysts predict
After some drug advertisers dropped out last week, Fox host Jeanine Pirro's show didn't air Saturday and isn't scheduled this week.
Gilead has the data it’ll need to begin a Truvada-to-Descovy switch in HIV prevention. But once Truvada generics hit, it might be a different story.
